-

New Thermo Fisher Scientific™ TSG Series Refrigerators Reduce Waste and Save Energy

TSG Series Laboratory and Pharmacy Refrigerators are designed and constructed sustainably in a zero-waste facility, offering a cleaner alternative and improved performance at a lower cost.

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, announced today a new line of Thermo Scientific TM TSG Series Refrigerators to ensure the safe storage of critical vaccines and pharmaceuticals for laboratory, pharmacy and clinical* environments.

The World Health Organization estimates that up to 50% of vaccines are wasted each year globally, primarily due to temperature control, logistics and shipment-related issues. The result is less vaccine availability for patients and caregivers and financial loss to physicians, researchers and institutions. TSG Series Laboratory and Pharmacy Refrigerators provide safe, effective storage of vaccines and other pharmaceuticals with less vaccine waste for our customers and is manufactured at our zero-waste-to-landfill facility in Asheville, North Carolina.

This new TSG series complies with NSF 456 performance standards, an American national standard that helps ensure storage equipment performs as intended to preserve the viability of vaccine doses. Compliance requires that vaccine storage equipment is tested against a rigorous protocol for construction and performance. The TSG series achieves this through optimum temperature performance, enhanced sample security, and an extended warranty doubled over previous models with full parts and labor.

“At Thermo Fisher Scientific, we’ve been providing our customers with cold storage solutions they can rely on for more than 80 years,” said Carlos Sevilla, Vice President and General Manager, Controlled Temperature Technologies. “The TSG Series is cost-effective, reliable, and provides greater energy efficiency and less vaccine waste, enabling our customers to make the world healthier, cleaner and safer.”

TSG Refrigerators also provide a 10% reduction in energy usage from previous models. They are Energy Star, EU F-Gas and U.S. EPA SNAP compliant and designed and constructed sustainably at a zero-waste facility in the U.S., furthering Thermo Fisher’s commitment to achieve Net-Zero Carbon Emissions by 2050.

For detailed product information and to order it now, click here.

*Note: These products are not considered as medical devices and have not been evaluated for use in environment or applications involving the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man or other animals.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team of more than 100,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Shannon Stoneking
Phone: 484-748-1279
Email: Shannon.Stoneking@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Shannon Stoneking
Phone: 484-748-1279
Email: Shannon.Stoneking@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom